Collegium Pharmaceutical, Inc., today announced that it has raised a $50 million financing. Collegium plans to use the proceeds of this financing to advance its lead abuse-deterrent product candidate, Xtampza ER through potential FDA approval and commercial launch as well as to fund operational growth and other pipeline development programs.
